Sichuan Biokin chases Hong Kong listing after BSM drug deal
The biopharma company has yet to market any products but one of its antibody-drug conjugates is being jointly developed in a lucrative collaboration with Bristol Myers Squibb Key Takeaways: Sichuan…
RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
Recent Articles
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
